Events & Presentations

Upcoming Events
Date Event Details Remind Me
Oct 5, 2023
2023 Annual Northeast Amyotrophic Lateral Sclerosis Consortium (NEALS) Meeting
Type: Poster Presentation
Title: Preclinical Profile of ARO-SOD1, an siRNA Therapy for SOD1-ALS
 
Oct 10, 2023
BMO Biopharma Spotlight Series: (R) Evolution of RNA Therapies
Type: Fireside Chat Presentation
Oct 18, 2023
Cracking the Code: The Dawn of Nucleic Acid Medicines
Type: Poster Presentation
Title: Rank Order TRiMTM Activity Correlates with RISC Loading and Can Be Enhanced by cPrP Modification
 
Oct 22, 2023
The 3rd International Research Conference on Neurodegenerative Diseases (IRCND 2023)
Type: Oral Presentation
Title: Preclinical Profile of ARO-SOD1, an siRNA Therapy for SOD1-ALS
 
Archived Events
Date Event Details
Feb 4, 2021 4:30 PM EST
Arrowhead Pharmaceuticals 2021 First Quarter Results
Dec 12, 2020 12:55 PM EST
20th Gordon L. Snider Critical Issues Workshop – The Promise of Gene-based Interventions in Alpha-1 Antitrypsin Deficiency
James Hamilton, M.D., MBA, Arrowhead’s senior vice president of discovery and translational medicine, will deliver an oral presentation titled, “Arrowhead’s approach to gene silencing - ARO-AAT for liver disease in Alpha-1 antitrypsin deficiency”
Dec 10 - Dec 12, 2020
National Lipid Association Scientific Sessions 2020
Dec 1 - Dec 3, 2020
32nd Piper Jaffray Annual Virtual Healthcare Conference
December 2, 2020 – Chris Anzalone, Ph.D., Arrowhead’s president and CEO, will participate in a fireside chat presentation. Recording is available on demand
Nov 23, 2020 4:30 PM EST
Arrowhead Pharmaceuticals 2020 Year End Results
Nov 19, 2020 1:30 PM EST
ARO-ANG3 KOL Webinar
KOL: Ira Goldberg, M.D., New York University Langone School of Medicine
Nov 18, 2020 11:30 AM EST
ARO-APOC3 KOL Webinar
KOL: Christie Ballantyne, M.D., Baylor College of Medicine
Nov 17 - Nov 19, 2020
Jefferies Virtual London Healthcare Conference
November 19, 2020, 2:40 p.m. GMT – Chris Anzalone, Ph.D., Arrowhead’s president and CEO, will participate in a fireside chat presentation.
Nov 13 - Nov 16, 2020
The Liver Meeting Digital Experience, the Annual Meeting of the American Association for the Study of Liver Disease (AASLD)
Title: ARO-AAT Reduces Serum and Intra-hepatic Z-AAT Protein in PIZZ Alpha-1 Antitrypsin Deficient Patients with Liver Disease Leading to Improvements in Clinically Relevant Liver Biomarkers
Authors: Pavel Strnad, et al.
Publication Number: LP14
Session: Late-breaking Abstract Posters
Nov 13 - Nov 17, 2020
American Heart Association (AHA) Scientific Sessions 2020

Title: Pharmacodynamic effect of ARO-ANG3, an investigational RNA interference therapeutic targeting hepatic angiopoietin-like protein 3, in patients with hypercholesterolemia
Authors: Gerald F. Watts, et al.
Session: Advances in Understanding and Treatment of Dyslipidemia and New Therapies for CVD

Title: Pharmacodynamic effect of ARO-APOC3, an investigational hepatocyte-targeted RNA interference therapeutic targeting apolipoprotein C3, in patients with hypertriglyceridemia and multifactorial chylomicronemia
Authors: Christie Ballantyne, presenting on behalf of Peter Clifton, et al.
Session: Advances in Understanding and Treatment of Dyslipidemia and New Therapies for CVD

Title: Safety, Tolerability and Efficacy of Single-Dose AMG 890, a Novel siRNA Targeting Lp(a), in Healthy Subjects and Subjects with Elevated Lp(a)
Authors: Michael J. Koren, et al.
Session: Advances in Understanding and Treatment of Dyslipidemia and New Therapies for CVD